Patents by Inventor Alfred Hausladen

Alfred Hausladen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY
    Publication number: 20140235528
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Application
    Filed: April 24, 2014
    Publication date: August 21, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Inhibiting GS-FDH to Modulate No Bioactivity
    Publication number: 20120245116
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Application
    Filed: June 8, 2012
    Publication date: September 27, 2012
    Applicant: Duke University
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Inhibiting GS-FDH to modulate no bioactivity
    Patent number: 8217006
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: July 10, 2012
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY
    Publication number: 20100015121
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Application
    Filed: September 24, 2009
    Publication date: January 21, 2010
    Applicant: DUKE UNIVERSITY
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Inhibiting GS-FDH to modulate no bioactivity
    Patent number: 7615535
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: November 10, 2009
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Inhibiting GS-FDH to modulate no bioactivity
    Publication number: 20070111949
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Application
    Filed: December 29, 2006
    Publication date: May 17, 2007
    Inventors: Jonathan Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Inhibiting GS-FDH to modulate NO bioactivity
    Patent number: 7179791
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: February 20, 2007
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Therapies using hemoproteins
    Patent number: 7112563
    Abstract: Herein it is shown that hemoproteins (e.g., Ascaris hemoglobin, myoglobin, flavohemoglobins) have NO-consuming and deoxygenase activities. The invention provides a method of reducing the concentration of oxygen and/or nitric oxide in a mammal. The method of the invention comprises administering a therapeutically effective amount of a hemoprotein having NO-activated deoxygenase activity or an enzymatically active fragment thereof to a mammal. The method can be used to treat a mammal having pathologically proliferating cells, such as a tumor. In one embodiment, the hemoprotein is administered to reduce the oxygen concentration of a tumor. In another embodiment, the hemoprotein is administered together with a cytotoxic agent to treat a mammal having a tumor. The invention also provides a method of enzymatically generating toxic reactive oxygen species in a mammal for therapeutic purposes. The method comprises administering a therapeutically effective amount of a hemoprotein to a mammal.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: September 26, 2006
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Alfred Hausladen
  • Inhibiting GS-FDH to modulate NO bioactivity
    Publication number: 20020128205
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Application
    Filed: January 11, 2001
    Publication date: September 12, 2002
    Applicant: DUKE UNIVERSITY Office of Science and Technology
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Therapies using hemoproteins
    Publication number: 20010031727
    Abstract: Herein it is shown that hemoproteins (e.g., Ascaris hemoglobin, myoglobin, flavohemoglobins) have NO-consuming and deoxygenase activities. The invention provides a method of reducing the concentration of oxygen and/or nitric oxide in a mammal. The method of the invention comprises administering a therapeutically effective amount of a hemoprotein having NO-activated deoxygenase activity or an enzymatically active fragment thereof to a mammal. The method can be used to treat a mammal having pathologically proliferating cells, such as a tumor. In one embodiment, the hemoprotein is administered to reduce the oxygen concentration of a tumor. In another embodiment, the hemoprotein is administered together with a cytotoxic agent to treat a mammal having a tumor. The invention also provides a method of enzymatically generating toxic reactive oxygen species in a mammal for therapeutic purposes. The method comprises administering a therapeutically effective amount of a hemoprotein to a mammal.
    Type: Application
    Filed: January 8, 2001
    Publication date: October 18, 2001
    Applicant: Duke University Medical Center
    Inventors: Jonathan S. Stamler, Alfred Hausladen